TrialThe Lancet. Oncology2011

Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study.

Stephen M Ansell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.